Summary
Moderna's shares surged by 95% following the successful final-stage trial of its mRNA-based cancer drug, marking a significant milestone as the first successful mRNA cancer therapy.
Moderna Shares Skyrocket 95% After Successful Final-Stage mRNA Cancer Drug Trial
HyperFast News
Related news
Moderna's Shift to Cancer Company Lifts Stock Up 177%
14 Sept 2026, 5:54 pm · News
Moderna's Experimental mRNA Cancer Treatment Progresses, Shares Spike
14 Sept 2026, 5:54 pm · News
Moderna and Merck's Personalized mRNA Vaccine Shows Promise Against Melanoma in Late-Stage Trial, Stocks Soar
14 Sept 2026, 5:54 pm · News
